Indo-U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03)

archived

Purpose. Scientific cooperation between India and the U.S. has taken place under a variety of bilateral umbrella agreements, including the Indo-U.S. Science and Technology (SandT) Sub-Commission, the Gandhi-Reagan SandT Initiative, the U.S.-India Fund, and the current SandT Cooperation Agreement. Building upon these agreements and initiatives, representatives of the United States and the Government of India signed a Memorandum of Understanding on July, 9 1987 implementing the Indo-U.S. Vaccine Action Program (VAP) in order to expand collaborative vaccine research. The goal of the VAP is to support collaborative vaccine-related research projects that ultimately reduce the burden of infectious diseases of importance in India, the U.S., the South Asian region and globally. Applications are encouraged from organizations/institutions that propose to conduct vaccine-related research through well-established collaborations with Indian investigators on the following: dengue, influenza (including avian influenza), HIV/AIDS, and tuberculosis. Basic, translational, clinical, or epidemiological vaccine research may be proposed. Clinical trials will not be supported by this initiative. Mechanism of Support. This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications, which will provide U.S. dollar support of vaccine-related research in India and the United States and augment current VAP activities. Investigators from U.S. and Indian institutions are eligible to apply. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.

High